Reviva Pharmaceuticals Holdings (RVPH) Common Equity (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Common Equity of $17.4 million for Q1 2026, up 101.68% sequentially from $8.6 million in Q4 2025, and up 491.04% YoY from $3.0 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Common Equity (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Common Equity for 9 years, with the latest figure at $17.4 million in Q1 2026.
- Quarterly Common Equity rose 491.04% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.4 million (up 491.04% YoY) and the FY2025 annual result came in at $8.6 million, up 964.23% from the prior year.
- Common Equity rose to $17.4 million in Q1 2026 per RVPH's latest filing, from $8.6 million in the prior quarter.
- Over five years, Common Equity peaked at $103.5 million in Q4 2022 and troughed at -$12.8 million in Q3 2023.
- A 5-year average of $9.4 million and a median of $1.6 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity slumped 232.83% in 2024, then soared 964.23% in 2025.
- Over 5 years, Common Equity stood at $103.5 million in 2022, then plunged by 94.47% to $5.7 million in 2023, then sank by 85.79% to $812572.0 in 2024, then jumped by 964.23% to $8.6 million in 2025, then soared by 101.68% to $17.4 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $17.4 million, $8.6 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 9.79 Bn |
| 10 | Reviva Pharmaceuticals Holdings | 6.40 Mn | 6.40 Mn | - | 15.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.21 Mn |
| Mar 31, 2026 | 17.44 Mn |
| Dec 31, 2025 | 8.65 Mn |
| Sep 30, 2025 | 4.55 Mn |
| Jun 30, 2025 | -459,147.00 |
| Mar 31, 2025 | -4.46 Mn |
| Dec 31, 2024 | 812,572.00 |
| Sep 30, 2024 | -9.98 Mn |
| Jun 30, 2024 | -6.04 Mn |
| Mar 31, 2024 | -1.35 Mn |
| Dec 31, 2023 | 5.72 Mn |
| Sep 30, 2023 | -12.81 Mn |
| Jun 30, 2023 | -1.82 Mn |
| Mar 31, 2023 | 1.61 Mn |
| Dec 31, 2022 | 103.49 Mn |
| Sep 30, 2022 | 17.56 Mn |
| Jun 30, 2022 | 16.06 Mn |
| Mar 31, 2022 | 21.36 Mn |
| Sep 30, 2021 | 32.27 Mn |
| Jun 30, 2021 | 34.52 Mn |